North Central Cancer Treatment Group N0531: Phase II trial of weekly albumin-bound paclitaxel (ABI-007; Abraxane®) in combination with gemcitabine in patients with metastatic breast cancer

Alvaro Moreno Aspitia, Edith A. Perez

Research output: Contribution to journalArticle

15 Citations (Scopus)
Original languageEnglish (US)
Pages (from-to)361-364
Number of pages4
JournalClinical Breast Cancer
Volume6
Issue number4
StatePublished - 2005

Fingerprint

gemcitabine
Taxoids
Pharmacogenetics
Breast Neoplasms
Neoplasms
Therapeutics
Albumin-Bound Paclitaxel

Keywords

  • Dose modifications
  • First-line chemotherapy
  • Pharmacogenetics
  • Taxanes

ASJC Scopus subject areas

  • Cancer Research

Cite this

@article{1a0189362c9c428aa4cc3e49fd7787ac,
title = "North Central Cancer Treatment Group N0531: Phase II trial of weekly albumin-bound paclitaxel (ABI-007; Abraxane{\circledR}) in combination with gemcitabine in patients with metastatic breast cancer",
keywords = "Dose modifications, First-line chemotherapy, Pharmacogenetics, Taxanes",
author = "{Moreno Aspitia}, Alvaro and Perez, {Edith A.}",
year = "2005",
language = "English (US)",
volume = "6",
pages = "361--364",
journal = "Clinical Breast Cancer",
issn = "1526-8209",
publisher = "Elsevier",
number = "4",

}

TY - JOUR

T1 - North Central Cancer Treatment Group N0531

T2 - Phase II trial of weekly albumin-bound paclitaxel (ABI-007; Abraxane®) in combination with gemcitabine in patients with metastatic breast cancer

AU - Moreno Aspitia, Alvaro

AU - Perez, Edith A.

PY - 2005

Y1 - 2005

KW - Dose modifications

KW - First-line chemotherapy

KW - Pharmacogenetics

KW - Taxanes

UR - http://www.scopus.com/inward/record.url?scp=28344431971&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28344431971&partnerID=8YFLogxK

M3 - Article

C2 - 16277889

AN - SCOPUS:28344431971

VL - 6

SP - 361

EP - 364

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

SN - 1526-8209

IS - 4

ER -